Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis

Fig. 2

Primary efficacy endpoint of ACR20 at week 12 (with non-responder imputation). a Difference (95% CI) between PF-06410293 and adalimumab-EU using a symmetric equivalence margin. b Difference (90% CI) between PF-06410293 and adalimumab-EU using an asymmetric equivalence margin. Abbreviations: ACR20 American College of Rheumatology 20% improvement, Adalimumab-EU adalimumab sourced from the European Union, CI confidence interval, ITT intention-to-treat, PP per protocol

Back to article page